Helen Dakin joined the Health Economics Research Centre in February 2008. Before starting at HERC, she worked at Abacus International and completed her MSc in Economic Evaluation in Healthcare at City University. She previously graduated from Cambridge University with Masters and Bachelor's degrees in Biochemistry. In 2014, she completed a DPhil at the University of Oxford on the optimal methods for conducting economic evaluations of factorial clinical trials.
Her current projects include: the STAR trial, which evaluates radiotherapy alongside bevacizumab (Avastin) in age-related macular degeneration; the ACHE study, which evaluates clinical tools and thresholds for selecting patients for joint replacement; and the KAT trial, which assesses the cost-effectiveness of different types of knee replacement component.
Research paper on factors influencing NICE decisions available here.
Lifetime cost-effectiveness simulation of exenatide once-weekly in type 2 diabetes: evidence from the EXSCEL trial
Becker F. et al, (2018), DIABETOLOGIA, 61, S366 - S366
Impact of exenatide on medical costs and health utilities in type 2 diabetes: experience from EXSCEL
Reed SD. et al, (2018), DIABETOLOGIA, 61, S426 - S426
Partial factorial trials: Comparing methods for statistical analysis and economic evaluation
Dakin HA. et al, (2018), Trials
EXSCEL-Once-Weekly Exenatide Reduces Medical Resource Utilization in Patients with Type 2 Diabetes Mellitus
Reed SD. et al, (2018), DIABETES, 67
Associations between preoperative Oxford hip and knee scores and costs and quality of life of patients undergoing primary total joint replacement in the NHS England: an observational study.
Eibich P. et al, (2018), BMJ open, 8, e019477 - e019477